This article first appeared on GuruFocus.
AstraZeneca (NYSE:AZN), one of the world’s largest pharmaceutical companies with a major focus on oncology, ended its Phase III eVOLVE-Lung02 trial after an independent committee concluded that volrustomig combined with chemotherapy was unlikely to outperform existing treatment options in improving progression-free or overall survival. The study covered 895 patients with metastatic non-small-cell lung cancer across 25 countries, while U.S.-listed shares slipped 0.2% to $156.20.
The failed trial creates a hole in volrustomig’s future sales opportunity, but it is not a knockout blow for AstraZeneca’s broader growth story. According to Reuters, the lung-cancer indication represented roughly 20% of the drug’s projected peak-sales potential. With AstraZeneca previously targeting more than $5 billion in peak sales for volrustomig, the setback could remove around $1 billion of potential revenue. The company is still moving forward with other volrustomig studies in cancers including cervical cancer, head-and-neck cancer and mesothelioma, with no new safety concerns reported.
Investors appear to view this as a speed bump rather than a broken investment thesis. AstraZeneca offset the disappointment with positive results from other late-stage oncology programs, including advances involving Tagrisso and Enhertu combinations. The bigger question is execution: AstraZeneca has built its valuation around a powerful pipeline and a target of reaching $80 billion in revenue by 2030. Every failed trial makes that target harder to achieve and raises the importance of future drug launches.
AstraZeneca Halts Key Lung-Cancer Trial–But Shares Barely Flinch ยท us.finance.gurufocus
The valuation picture remains interesting. According to the GF Value chart, AstraZeneca traded at $156.30 versus a GF Value estimate of $179.72, putting the stock about 13% below its estimated intrinsic value. The market is clearly demanding proof from AstraZeneca’s pipeline, but the discount suggests investors may already be pricing in some execution risk. For long-term investors, the key debate is whether today’s uncertainty creates an opportunity before the company’s next wave of oncology growth arrives.